Chemotherapy-free treatments: are we ready for prime time?
Keywords: 
Chemotherapy
Epithelial ovarian cancer (EOC)
Genetic impairments
DNA
Issue Date: 
2019
Publisher: 
Elsevier BV
ISSN: 
0923-7534
Citation: 
Lorusso, D. (D.); Pignata, S. (S.); González-Martín, A. (Antonio). "Chemotherapy-free treatments: are we ready for prime time?". Annals of Oncology. 30 (4), 2019, 497 - 498
Abstract
Epithelial ovarian cancer (EOC) is most frequently diagnosed at an advanced stage and, despite high response rates to initial taxane-platinum-based chemotherapy, more than 70% of patients will develop recurrent disease and will receive several chemotherapy treatments. At present, the 5-year overall survival (OS) for women diagnosed with stage III–IV disease is 46% and patients with genetic impairments of DNA repair pathways [BRCA mutations and in general homologous recombination deficiency (HRD)] live longer and possibly will receive even more lines of chemotherapy.

Files in This Item:
Thumbnail
File
PIIS0923753419311354.pdf
Description
Size
70.64 kB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.